Corrigendum
- PMID: 34139054
- PMCID: PMC8450927
- DOI: 10.1111/jdv.17247
Corrigendum
Erratum for
-
Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients.J Eur Acad Dermatol Venereol. 2021 Jan;35(1):e15-e17. doi: 10.1111/jdv.16956. Epub 2020 Oct 21. J Eur Acad Dermatol Venereol. 2021. PMID: 32977355 Free PMC article. No abstract available.
-
Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men.J Eur Acad Dermatol Venereol. 2021 Jan;35(1):e13-e15. doi: 10.1111/jdv.16953. Epub 2020 Oct 21. J Eur Acad Dermatol Venereol. 2021. PMID: 32977363 Free PMC article. No abstract available.
-
Clinical symptoms of hyperandrogenic women diagnosed with COVID-19.J Eur Acad Dermatol Venereol. 2021 Feb;35(2):e101-e104. doi: 10.1111/jdv.17004. Epub 2020 Nov 8. J Eur Acad Dermatol Venereol. 2021. PMID: 33089570 No abstract available.
-
5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia.J Eur Acad Dermatol Venereol. 2021 Apr;35(4):e243-e246. doi: 10.1111/jdv.17021. Epub 2020 Nov 22. J Eur Acad Dermatol Venereol. 2021. PMID: 33135263 No abstract available.
References
-
- McCoy J, Cadegiani FA, Wambier CGet al. 5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia. J Eur Acad Dermatol Venereol 2021; 35: e243–e307. - PubMed
-
- Cadegiani FA, Lim RK, Goren Aet al. Clinical symptoms of hyperandrogenic women diagnosed with COVID‐19. J Eur Acad Dermatol Venereol 2021; 35: e97–e163. - PubMed
Publication types
LinkOut - more resources
Full Text Sources